Thermo Fisher Dec 15, 2025 Thermo Fisher adds chemically defined E. coli fermentation medium and feed to Gibco Bacto line - R&D World
Endpoints News Dec 15, 2025 Aviceda's geographic atrophy drug fails mid-stage study. Can it do better in Phase 3?
FierceBiotech Dec 15, 2025 Kyverna gains clear view to first CAR-T approval for autoimmune disease after 'truly remarkable' SPS readout
Endpoints News Dec 15, 2025 Areteia Therapeutics to wind down after terminating Phase 3 asthma studies
Endpoints News Dec 15, 2025 Immunome's rare tumor drug passes Phase 3 test, could challenge Merck KGaA
Thermo Fisher Dec 15, 2025 Thermo Fisher Expands Gibco Bacto CD Portfolio with New E. coli Media - Contract Pharma